[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6244 followers
Created: 2025-07-28 13:32:55 UTC

Cipla Q1 FY26: Strong Revenue Growth & Strategic Launches 🚀 | MCap 1,26,893.68 Cr

- Q1 FY26 revenue: ₹6,957 Cr | PAT: ₹1,298 Cr (18.7% margin, +10.2% YoY)
- One India biz crosses ₹3,000 Cr in opening quarter (+6% YoY)
- X new brands enter ₹100 Cr club (total 29), leads in X IPM therapies
- U.S. expansion: Launched Nano Paclitaxel & Nilotinib; biosimilar deal signed for Q2 FY26
- Albuterol holds XXXX% U.S. market share | Prep for generic Symbicort launch
- Consumer Health shines: Nicotex, Omnigel, Cipladine lead segments
- Africa +11% YoY (USD) | EMEU +8% despite geopolitical challenges
- R&D spend: ₹432 Cr (6.2% of revenue) | Net cash: ₹10,379 Cr
- FY26 EBITDA margin guidance maintained at 23.5%-24.5%
- GLP-1 plans underway (semaglutide in focus) | Indore facility reinspection expected soon

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/Gw8rt8baQAAfMy1.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949825399518822564/c:line.svg)

**Related Topics**
[india](/topic/india)
[mcap](/topic/mcap)
[quarterly earnings](/topic/quarterly-earnings)
[$ciplans](/topic/$ciplans)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1949825399518822564)